Long-term implications of bone loss in breast cancer.

  title={Long-term implications of bone loss in breast cancer.},
  author={Matti S. Aapro},
  volume={13 Suppl 1},
Cancer treatment-induced bone loss (CTIBL) is an emerging problem during long-term adjuvant therapy with aromatase inhibitors or ovarian-ablative therapy. CTIBL increases the risk of skeletal complications. Patients receiving adjuvant therapy for breast cancer should receive periodic bone mineral density (BMD) assessments, and those with clinically significant bone loss should be treated with bisphosphonates. Intravenous (i.v.) bisphosphonates (e.g., zoledronic acid) appear to be a very… CONTINUE READING